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Abstract
The  modern  research  on  molecular  basis  of  prostate  cancer  (PCa)  development
includes studies aiming to identify potential genetic markers which could be used in
diagnostics  and/or  monitoring of  PCa.  Genome-wide association studies  (GWASs)
have identified over  75  variants  associated with PCa risk.  One of  the  major  PCa-
related regions identified through GWASs is found to be a segment of 8q24. Other
important PCa-susceptibility regions are 17q12, 17q24, 10q11, and 19q13. Candidate-
gene based approach has also provided evidence of association between PCa risk and
genetic  variants  located in  functionally  significant  genes  (both protein-coding and
noncoding  RNA  genes)  involved  in  normal  prostatic  cell  growth,  malignant
transformation,  or  in  the  development  of  metastases.  Nevertheless,  the  success  of
these  studies  is  questionable,  since  numerous  candidates  for  PCa-susceptibility
variants were identified, but these results failed to replicate. The main aim of both
types  of  genetic  association  studies  on  PCa  is  the  identification  of  potential  PCa
genetic  markers  which  could  be  used  for  constructing  reliable  algorithms  for
evaluating the risk for PCa development and/or PCa progression.
Keywords: prostate cancer, association study, GWAS, candidate gene, validation
study, replication study
1. Introduction
Alarming statistics on prostate cancer (PCa) incidence and mortality, as well as the results of
epidemiological  studies,  have  led  to  focusing  research  efforts  on  discovering  molecular
mechanisms underlying its onset and progression [1]. Still, molecular basis of PCa pathogene‐
sis remains largely unknown, while the results of studies in this area of research suggest that
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PCa is one of the most genetically and molecularly heterogeneous malignant tumors [2]. Among
PCa cases, most are sporadic, while a significantly smaller percent represents familial type,
including hereditary cases. High-penetrability PCa-related loci are not common in popula‐
tions and are found to be associated with hereditary PCa. Since PCa represents a multifactori‐
al disease with polygenic basis, and sporadic cases are much more frequently diagnosed, most
of the research in the area of PCa molecular genetics has focused on genetic variants with low
penetrability [3].
The modern research on molecular basis of PCa development includes studies aiming to
identify potential genetic markers which could be used in diagnostics and/or monitoring of
PCa [1]. This is of utmost importance, since one of the major issues in clinical practice related
to PCa is a large percent of latent PCa among newly diagnosed [4]. The overdiagnosis of PCa
in early diagnosed cases, due to indolent forms, leads to unnecessary morbidity because of
application of invasive therapeutic procedures [5]. This led to focusing the research efforts on
discovering genetic markers that could be used for assessing the biological potential of early
diagnosed PCa. Therefore, the use of these genetic markers, together with standard prognostic
parameters of PCa progression, which include initial serum PSA level, Gleason score, and
clinical stage, could greatly improve the current clinical protocols by being implemented in
algorithms for evaluating the patient’s risk of PCa and/or PCa aggressiveness [1].
Studies aiming to identify potential PCa-related loci are designed as case-control or case-only
studies, which evaluate the differences in genotype distributions between cases and controls,
as well as between different groups of patients, classified according to clinical characteristics.
The most validated loci associated with PCa risk were identified through Genome-wide
association studies (GWAS) [6]. Nevertheless, numerous PCa-related genetic variants were
found in studies based on selected candidate genes [7].
2. Linkage analyses and high-penetrability loci
Linkage analyses have led to identification of the first high-penetrability PCa susceptibility
loci [1]. These studies were based on analyses in hereditary PCa, which is a less frequent type
of PCa, and yielded high or moderate-penetrability loci, such as HPC1 (eng. Hereditary Prostate
Cancer 1, HPC1) mapped in chromosomal region 1q24-25 [8], PCAP (eng. Predisposing for Cancer
Prostate, PCAP) mapped in 1q42.2-43 [9] and HPCX (eng. Hereditary Prostate Cancer on X
Chromosome, HPCX) located in 1q42.2-43 [10]. Later on, additional linkage studies identified
several other loci primarily associated with familial PCa and rarely found to be altered in
sporadic type [1, 3]. Fine-mapping of these regions has led to identifying several candidate
genes, such as RNASEL or ELAC2 [11, 12]. Nevertheless, since the major percent of PCa is
sporadic types, numerous studies have focused on identifying low-penetrability loci associ‐
ated with not only sporadic PCa, but also potentially contributing to the risk of developing
familial type of disease [3]. These studies were not designed as linkage, but instead as genetic
association studies with case–control matched groups.
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3. Genome-wide association studies
The Human genome project was critical for making high-throughput genome-wide analyses
possible. Not only that this project yielded DNA sequence information but also provided basis
for development of methodology, including high-throughput genotyping assays, as well as
software tools for analyzing large amount of genetic data [13]. Therefore, sequencing of human
DNA provided basis for GWASs, including those on PCa [14].
To date (February 2016), GWASs have identified over 75 variants associated with prostate
cancer risk, predominantly in populations of European ancestry (Figure 1) [15, 16]. The first
GWASs were conducted in 2007, for which a large collection of samples were obtained from
PCa patients and healthy controls, as well as databases that included clinical data of patients
were constructed [17–19]. The necessity of a large number of subjects for this type of study was
obvious even in this early period of conducting GWASs.
Figure 1. Ideograms of human chromosomes with marked PCa susceptibility loci identified through GWASs. Ideo‐
grams were obtained from NCBI Map Viewer, while GWAS hits were found in NHGRI-EBI GWAS catalog.
As in other complex diseases, PCa GWASs are usually designed in a multistage manner, with
the whole set of tag-single nucleotide polymorphisms (tag-SNPs) being evaluated in the first
phase, and only subsets of the most significant SNP being replicated in much larger groups of
patients and controls in next phases [20, 21]. Thus, repeating the tests yields the most significant
results [20].
The results of initial GWASs showed that most of the PCa-associated genetic variants are
located in so-called “gene-deserts”. The lack of protein-coding genes in these regions was
explained by the supposed presence of regulatory sequences of major proto-oncogenes and
tumor-suppressive genes [22, 23]. Today, another explanation is also the presence of genes
encoding regulatory RNA molecules within PCa-risk regions [24].
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3.1. 8q24 region
One of the major PCa-related regions was found to be 8q24. Within approximately 1 million
base pairs segment of 8q24 reside multiple variants associated with PCa [25]. This region was
first identified as associated with PCa susceptibility in a genome-wide linkage study conducted
in Icelandic population [26]. Later on, the association of genetic variants within this region
with PCa risk was shown in initial GWASs from 2007. Gudmunsson et al., Haiman et al. and
Yeager et al. have shown the association between previously reported rs1447295 and PCa risk
[17–19]. Also, these first GWASs identified other PCa susceptibility variants within 8q24,
rs6983267, and rs16901979. Afterward, GWASs have provided evidence for association of other
single-nucleotide genetic variants (SNVs) from 8q24 with PCa risk, such as rs4242382,
rs7017300, and rs7837688 [27, 28]. In the recent years, by implementing clinical data and by
using case-only design, both GWASs and validation studies have provided evidence for an
association of several loci within 8q24 with PCa aggressiveness or survival [29–32].
PCa-susceptibility region within 8q24 was defined as gene desert, since no known protein-
coding genes were located within it. Nevertheless, the possible biological explanation for the
effect of genetic variants located in 8q24 on PCa risk was their influence on the regulation of
the expression of nearby genes, mainly C-MYC. It was suggested that regulatory sequences
controlling the transcription rate of C-MYC gene were located in 8q24, and that functional
genetic variants which are in strong linkage disequilibrium (LD) with PCa susceptibility locus
or several loci effect the sequence and therefore the function of regulatory elements [23].
Previous studies on molecular mechanisms of PCa pathogenesis have shown the functional
significance of C-MYC, both by analyzing mutational signatures of malignant prostate tissue
and by conducting functional analyses in cell cultures, which included stimulation or silencing
of C-MYC expression [33]. Other than prostate cancer, several other malignancies were
associated with 8q24, including breast and colorectal cancer. Some of the subregions of 8q24
associated with these cancers are found to overlap with those related to PCa, while others differ
(Figure 2) [34].
Figure 2. PCa risk-associated regions within 8q24. Lower part of the figure represents Haploview output for a segment
of 8q24 (ch8:127500000..129000000) with marked subregions associated with PCa in GWASs. The upper part of the fig‐
ure is a representation of genes located in the region of interest obtained from Ensembl genome browser (GRCh37).
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3.2. 17q12
17q12 is another PCa susceptibility region identified through initial GWAS. Two of the genetic
variants located in 17q12, rs7501939 and rs3760511, were found to be associated with the risk
of developing PCa in the study by Gudmundsson et al. conducted in 2007 [35]. In this GWAS,
minor alleles of these two single nucleotide genetic variants were found to confer the increased
risk of PCa in cohorts of participants from Iceland, Netherlands, and the USA, while in the
group of Hispanics this genetic association was not shown [35]. The results of this GWAS were
further validated in multiple populations, mostly of European origin [36–43]. Validation
studies were even conducted in Africans in which genetic association studies on PCa are scarce
[37, 44–47]. The most recent meta-analysis of both GWASs and validation studies has also
shown the association of these genetic variants with PCa risk [43].
SNVs rs7501939 and rs3760511 are located in the first intron of the hepatocyte nuclear factor
1 β(HNF1β ) or transcription factor 2 (TCF2) which is a transcription factor showing tissue-
specific expression pattern. Therefore, the association of genetic variants located in 17q12 with
PCa risk could be explained by the effect of functional genetic variants on HNF1β function or
expression [41].
3.3. 17q24
Another PCa-susceptibility region on chromosome 17 is 17q24. Genetic variants located within
this region which were found to be associated with PCa are intergenic variants. Similar to 8q24
genetic variants, those located in 17q24 are found in a gene desert, probably harboring multiple
regulatory sequences controlling the expression of surrounding genes [48]. One of the most
proximal genes is SOX9, which is an important proto-oncogene in prostatic tissue. Recent
findings have shown the location of PCa-associated genetic variants in an enhancer looping
to SOX9 gene [48]. Among these genetic variants is a tag-SNP previously identified through
GWAS, as well as potentially functional genetic variants found by deep sequencing of PCa-
susceptibility region [35, 48].
3.4. 10q11
Two out of the three GWASs, which were published in 2008 in the same issue of Nature
Genetics, have identified PCa-associated genetic variants in the region 10q11 [27, 36]. After‐
ward, other studies have provided additional evidence to support the association between
10q11 and PCa susceptibility, including both GWASs and validation studies [49–55]. One of
these PCa risk-associated genetic variants was located in the close proximity of the transcrip‐
tion start site of the gene Microseminoprotein B (MSMB ) which encodes a tumor-suppressor,
and was, therefore, even considered as potentially functional. For the risk allele of this genetic
variant, it was further shown to affect the expression of MSMB gene in a negative manner [56,
57]. The other gene in proximity to this genetic variant is Nuclear receptor coactivator 4 (NCOA4).
NCOA4 protein interacts with androgen receptor (AR) and acts as corepressor of androgen-
responding genes. Therefore, functional genetic variants in LD with GWAS hits could
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potentially contribute to PCa risk by affecting the expression of these two genes, or others in
proximity [58].
3.5. 19q13
Region 19q13 harboring kallikrein genes KLK2 and KLK3 was found to be associated with PCa
susceptibility through GWASs [59]. Several genetic variants associated with PCa risk were
located in KLK3 gene, such as missense SNV rs17632542 identified by fine-mapping of PCa-
associated subregion 19q13.33. These genes encode serine-proteases, one of which is PSA, used
for PCa diagnosis and disease monitoring. Therefore, the association of PCa-risk genetic
variants with serum PSA level was evaluated, yielding statistically significant results for
potentially functional SNV rs17632542 [15, 59].
Another subregion associated with PCa risk is 19q13.4 in which a GWASs hit is in strong LD
in Chinese population with germline deletion affecting LILRA3 gene, involved in inflamma‐
tory pathways [60].
4. Candidate gene-based approaches
Even before GWASs, the necessity of conducting association studies in order to identify low
and moderate penetrability genetic variants that contribute to PCa risk was obvious. Therefore,
numerous candidate genes were analyzed for genetic variants associated with PCa, with
questionable success due to false discoveries and the lack of replication [61]. Candidates were
selected based on their potential functional significance in normal prostatic cell growth,
malignant transformation, or in the development of metastases. Therefore, among these
candidate genes are those encoding proteins involved in androgen signaling, cell-cycle control
mechanisms, major tumor-suppressors, or proto-oncogenes, as well as those involved in
cellular adhesion or communication with surrounding cellular or matrix components of
prostate epithelium [62, 63]. This implies the need for previous knowledge when designing
case-control studies using candidate gene approach [64].
Even though these studies were common before GWASs, they are still conducted in numerous
populations, aiming to confirm previously found associations, or to identify new ones by
analyzing other candidates, selected by using modern research results, such as those involved
in regulatory functions of non-coding RNAs [65].
4.1. Protein-coding genes
4.1.1. Androgen signaling
Since androgen signaling is essential for growth and survival of prostate epithelial cells, genes
involved in androgen biosynthesis, signal reception and transduction, as well as in androgen
metabolism have emerged as candidates for case–control studies [63]. Most of these studies
involved Androgen receptor (AR), as the major component of androgen signaling and
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regulation of expression of androgen-responding genes. Among these studies, major percent‐
age relied on analyzing the potential association of the length of CAG repeat string with exon
1 which encodes a poly-glutamine tract of AR with PCa risk [66]. This homopolymeric tract is
located in N-terminal domain of AR, which possesses transactivational properties and its
length is inversely correlated with transactivation function [67]. Even though initial results
were promising, the supposed association was not confirmed in a large percentage of later
studies, and the effect sizes were not large enough to support the substantial biological role.
Therefore, the association of this genetic variant with PCa risk remains controversial [68–70].
Another three-nucleotide (GGN) repeat string, encoding polyglycine tract in AR, was analyzed
for potential association between its length and PCa risk. This repeat string is also located in
exon 1, but less studied than the CAG repeat tract, possibly due to technical problems in
amplifying GC-rich DNA regions [71]. The effect of the length of GGN repeat string on
transactivational properties of AR is still unclear, and the other proposed mechanism of
potential functional significance is the effect on AR translation [72]. Studies on the potential
association of this microsatellite on PCa risk and progression yielded contrasting results [73–
79].
Mixed results were also found for SRD5A2 (type II steroid 5α-reductase), which is the major
enzyme converting testosterone to dihydrotestosterone. Similarly, studies analyzing genetic
variants within CYP17, CYP19A, HSD17B, and HSD3B have shown initial promising results,
lacking consistent validation [63, 80].
4.1.2. Carcinogen metabolism
Among genes involved in cell detoxification, those encoding glutathione-S-transferases have
been mostly analyzed. Nevertheless, most of these studies yielded insignificant results on
association with PCa risk [81]. Other frequently analyzed genes involved in metabolism of
carcinogens are PON1, CYP1A1, CYP1B1, and CYP3A4 [80, 82–85].
Two genetic variants within PON1 have been analyzes in multiple populations, L55M and
Q129R. The results to date are inconclusive, but the meta-analysis conducted in 2012 suggested
the association of L55M missense variant with PCa risk [82]. Also, a recent meta-analysis on
only three PCa studies and Q129R showed statistically significant association for several
genetic models of association [83].
The most commonly analyzed SNVs in CYP1A1 are missense variants rs1048943 (p.Ile462Val)
and rs4646903, which are also called MspI polymorphisms, since they alter the recognition site
for MspI restriction enzyme. Numerous studies and also the recent meta-analyses showed the
association between these SNVs and PCa risk [84–86].
The results obtained for genetic variants in CYP1B1 and CYP3A4 are controversial, with the
recent meta-analyses suggesting the association of L432V, N453S, and A119S polymorphisms
of CYP1B1 and A392G in CYP3A4 with PCa susceptibility [87, 88].
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4.1.3. DNA repair, cell cycle control, and apoptosis
Dysfunctions of DNA repair pathway, apoptosis regulation, and cell cycle control mechanisms
alter the cells response to DNA damage and lead to uncontrolled proliferation, progression
and metastasis of malignant diseases. Also, genetic variants in genes involved in these
processes could potentially attribute to cancer susceptibility and/or progression risk [62].
Among the genes analyzed for association between genetic variants and prostate cancer risk
or aggressiveness are XRCC1 and XRCC3 (X-ray repair cross-complementing proteins 1 and
3), ERCC1 and ERCC2 (Excision repair cross-complementing rodent repair deficiency,
complementation group 1 and 2), LIG4 (Ligase IV), ATM (Ataxia telangiectasia mutated), XPD
(Xeroderma pigmentosum group D), MDM2 (Human mouse double-minute 2 protein),
CDKN1A, and CDKN1B (Cyclin-Dependent Kinase Inhibitors 1A, and 1B), CCND1 (Cyclin D1)
as well as BCL2 (B-cell lymphoma 2) and TP53 (tumor protein p53) [89–102]. Genetic variants
within most of these genes were found to be associated with PCa aggressiveness or response
to therapy. Nevertheless, these results were seldom replicated in multiple populations.
The most common SNVs in XRCC1 studied in case–control studies on cancer risk are rs1799782
(p.Arg194Trp), rs25489 (p.Arg280His), and rs25487 (p.Arg399Gln) [89, 103]. These genetic
variants were also analyzed for their potential association with PCa risk in numerous studies,
but the obtained results were inconsistent [89, 90]. For rs25489, association with radiation-
induced late toxicity in PCa patients was also shown [104]. Similarly, rs861539 (p.Thr241Met)
in XRCC3 was found to be associated with early adverse effects induced by radiotherapy, based
on quantitative data synthesis of 6 studies [105].
A recent study conducted in Spain showed the association of rs11615 in ERCC1 and rs17503908
in ATM with PCa aggressiveness [93]. Genetic variants in the same chromosomal region as
ERCC1 were previously analyzed in a large study that provided opposing results. Neverthe‐
less, this previous study was designed as to include subjects from multiple populations, and
its results could therefore be influenced by genetic backgrounds of study participants [93, 106].
Among genetic variants located in MDM2, missense variant SNP309 in the promoter region
was most frequently analyzed. This SNV was found to be associated with both PCa risk and
aggressiveness in multiple studies [107, 108]. The first study on this subject yielded no evidence
of the supposed association [109]. Nevertheless, results obtained in several later studies
suggested the association of SNP309 with the risk of PCa progression to the more advanced
stage, or the statistical trend of significance was reached [108].
Numerous studies conducted on a potential association between CCND1 genetic variant
rs603965 (p.Ala870Gly) and PCa risk, yielding inconsistent results [99]. This SNV was found
to affect alternative splicing and thus alter the C-terminal domain. Other genetic variants
within this gene were shown to be associated with the risk of PCa biochemical reoccurrence
after radical prostatectomy [110].
The most extensively analyzed SNV located in TP53 gene is rs1042522 (p.Arg72Pro). This
genetic variant was found to be associated with PCa risk, especially among Caucasians [102].
When it comes to BCL2, encoding the founding member of apoptosis regulatory proteins,
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promoter SNV c.-938C > A was associated with PCa risk, although lacking replication, as well
as with disease-free survival and biochemical recurrence of PCa after radical prostatectomy
[100, 101, 111].
4.1.4. Vitamin D signaling
Vitamin D signaling in PCa has stimulatory effect on apoptosis, as well as inhibitory effect on
the progression of cell cycle. Therefore, multiple genetic variants within the gene encoding the
receptor for vitamin D (VDR) were analyzed for their potential association with PCa risk and/
or progression. Most of them are loci named FokI, BsmI, ApaI, and T I, according to restriction
enzyme used for genotyping, Cdx2 in promoter region and polyA microsatellite, which were
most frequently tested [112–114].
Even though the initial results on these loci were promising, in multiple populations, they were
not replicated [113, 115]. The association of these genetic variants with PCa progression
parameters and the disease outcome also remains inconclusive [113, 116].
4.1.5. Chronic inflammation and angiogenesis
Numerous genes involved in chronic inflammation have been studies for association of genetic
variants that reside within them with PCa risk and/or progression [117]. Also, the importance
of vascular support to cancer growth stimulated the association studies on PCa analyzing
genetic variants located in angiogenesis-related genes [62]. Since these processes are code‐
pendent, numerous genes primarily found to be involved in chronic inflammation are also
discussed as angiogenesis-related genes, and vice versa.
Among the most important factors of chronic inflammation are TGF-β, COX2, TNF-α, and IL-1-
β, as well as PPAR-γ. To date, several SNVs in TGF-β1 have been identified as PCa-suscepti‐
bility variants, some of them also associated with PCa aggressiveness [118–123]. The studies
on the most of the chronic inflammation-related genes provided conflicting results [117].
There have been various PCa case–control studies involving Vascular endothelial growth factor
(VEGF) gene, encoding the important proangiogenic growth factor, as well as genes encoding
Interleukin 8 (IL-8 ) and Interleukin 10 (IL-10) [96, 124–128] for genetic variant rs1570360
[c.-1154G > A] located in the promoter region of VEGF, statistically significant association with
PCa risk was shown in several studies [126]. Most other VEGF genetic variants analyzed for
potential association with PCa risk and/or progression are also located in the promoter region
[126, 129–131]. These SNVs could be associated with transcription rate of VEGF [132], which
is positively correlated with tumor stage, Gleason score, as well as with shorter period of
disease-free survival [133].
Candidates for this type of studies were also genes encoding transcription factors which
regulate the expression of VEGF, such as Hypoxia inducible factor 1 (HIF1A ), Epidermal
growth factor (EGF ), and Lymphotoxin α (LTA). Nevertheless, except for HIF1A, association
of genetic variants within these genes with PCa risk was not shown, or was mostly found in
small sample studies and poorly replicated [62, 125, 126, 134].
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Some of the key regulators of angiogenesis are also fibroblast growth factors (FGFs). Therefore,
receptor FGFR4 gene has been analyzed for genetic variants associated with PCa risk and/or
progression. The most commonly tested SNV is a missense variant rs351855 (p.Gly388Arg),
found to be associated with PCa risk and aggressiveness in a relatively small number of studies
[135].
Among the most extensively analyzed candidate genes in PCa-related case-control studies are
NOS3 and NOS2A, encoding nitric oxide synthases [136]. Both endothelial and inducible nitric
oxide synthases, encoded by these genes, are enzymes that catalyze the production of NO from
L-arginine and L-citrulline amino acids [137]. Being the major producer of NO in endothelial
cells, eNOS, encoded by NOS3, is involved in the control of vascular tone and angiogenesis,
which is essential for tumor growth and the development of metastases. Yet, the synthesis of
NO is associated with apoptosis, which has the opposing effect on carcinogenesis [138].
Numerous genetic variants within these genes, especially NOS3, have been analyzed for
potential association with PCa risk and/or progression [136]. Most commonly analyzed SNVs
are -786 T > C (rs2070744) and 894G > T (rs1799983) [139–147], while several studies included
insertion-deletion polymorphism 4a4b located in intron 4 of NOS3 [140, 146, 148, 149]. For
rs1799983, which is a missense genetic variant, it was hypothesized to affect NOS3 stability
[150]. The other common SNV, rs2070744, affects promoter activity by allele C creating a
binding site with validation protein 1A (RPA1) [151].
Angiogenesis process and tumor invasion also require degradation of extracellular matrix and
basal membranes, which are catalyzed by matrix metalloproteinases. Among the genes
encoding this class of enzymes, MMP2 and MMP9 are analyzed for genetic variants associated
with PCa risk, and also for disease aggressiveness, due to their functional significance in tumor
invasiveness [139, 152–156]. Commonly analyzed genetic variant in MMP2 promoter is
rs243865. For minor allele of this SNV it was shown to be associated with reduced transcription
rate of MMP2 [157].
4.1.6. Cellular adhesion
Among genes involved in cellular adhesion, CDH1 encoding E-cadherin was the candidate
gene for the most case-control studies on PCa. Since aberrant expression of this gene is
correlated with the increased metastatic potential of PCa, genetic variants in its promoter
region were analyzed for potential association with PCa risk and progression [158, 159]. Most
extensively studied SNV−160C > A was found to affect CDH1 expression and was identified
as PCa susceptibility genetic variant in multiple populations [158, 160].
Only few studies also included genetic variants in genes encoding intercellular adhesion
molecules (ICAMs), proteins involved in cellular adhesion and signaling. The analyzed genetic
variants are those located in ICAM-1, ICAM-4, and ICAM-5 genes and need a further evaluation
for potential association with PCa risk and/or progression [161, 162].
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4.2. Long noncoding RNA genes
The potential involvement of long noncoding RNAs (lncRNAs) in prostate carcinogenesis was
suggested not only by the results of expression analyses that showed several known oncogenic
and/or tumor-suppressive lcnRNAs to be aberrantly expressed in malignant prostatic tissue
or plasma samples from patients with PCa but also by the identification of several PCa-specific
lncRNAs [163, 164].
Several SNVs in lncRNA genes were identified as PCa susceptibility variants in case–control
studies on PCa. In their study published in 2011, Jin et al. have stated that eight SNVs identified
to that time through GWAS are located in lncRNA intervals [165]. They also identified a SNV
in a putative lncRNA which was not later experimentally confirmed as a PCa-susceptibility
variants [165]. In a study published in 2013, Xue et al. have shown the association between two
tag-SNPs in Prostate cancer gene expression marker 1 (PCGEM1 ) and PCa risk in Chinese
population [166]. Genetic variant in another PCa-specific gene, prostate cancer associated 3
(PCA3), was analyzed for the length of a TAAA repeat string in the promoter region. This
genetic variant was also found to be associated with PCa risk [167]. In a GWAS published in
2014, Cook et al. have identified rs7918885 in RP11-543 F8.2 gene as a PCa-susceptibility SNV
in West African men, although GWAS statistical significance threshold was not reached [168].
Also, by using fine-mapping and resequencing of PCa-susceptibility subregion of 8q24,
lncRNA gene prostate cancer noncoding RNA 1 (PRNCR1) was found to be located between
the most significantly associated genetic variant [169].
4.3. MicroRNA genes
Dysregulation of diverse regulatory mechanisms based on microRNA activity has been
implicated in prostate carcinogenesis. Therefore, possibly functional genetic variants located
in microRNA genes emerged as potential PCa-associated loci. Among these genetic variants
are those that potentially influence microRNA biogenesis, stability of mature microRNAs,
efficiency of target gene regulation, as well as target specificity. By affecting these features of
microRNA regulatory mechanisms, microRNA SNVs could be associated with aberrant
expression of various important PCa-related oncogenes or tumor-suppressive genes [170–172].
MicroRNA genetic variants have been analyzed for their potential association with PCa in only
a few studies conducted in Asian populations and in a single population of European origin.
These studies have provided discordant results on the effects of genetic variants in rs2910164
in hsa-miR-146a [173–176], hsa-miR-196a2 [174, 176, 177], and rs3746444 in hsa-miR-499 gene on
PCa risk [174, 177]. In a recent study, rs4705342 located in hsa-miR-143 gene promoter was
found to be associated with the risk of developing PCa [178]. Since the number of conducted
studies is small, additional findings from multiple populations are needed in order to make
further conclusions.
Another SNV, rs895819 located in a gene encoding miR-27a, which is androgen-regulated and
stimulates the androgen signalization in a positive feedback loop, was found to be associated
with PCa risk, as well as with the development of distant metastases. Nevertheless, these
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results are derived from a single study on PCa risk and rs895819 conducted relatively recent
and needs further validation [177].
5. Replication, validation studies, and Meta-analyses
Differences in genetic backgrounds are an important issue in genetic association studies.
Therefore, interpretation of data requires discussing the potential differences between
populations. Therefore, in order to analyze such differences, multiple validation analyses are
conducted in various population and ethnicities. These studies are designed so that they
resemble as much as possible to the original study that yielded genetic associations, or the lack
of it. The ratio for conducting such studies is the possible lack of association between identified
PCa-susceptibility variants with PCa risk in certain populations, or the differences in effect
sizes [179]. Replication studies, conducted in confirmation group of participants from the same
population in which the initial results were found, is a method of checking reproducibility and
evaluating possible false positives and effect overestimation [179, 180].
Currently, replications and validations are conducted for both GWASs results, as well as for
results from candidate gene-based studies. Of utmost importance is conducting replication
and validation analyses of hits from studies with relatively small sample sizes, as well as with
poorly clinically characterized cases with the lack of data on possible confounders, or ques‐
tionable recruitment of controls [180]. Also, an important issue in case–control studies on PCa
is the type of control group, which is in some cases healthy controls, while in others group of
patients with benign prostatic hyperplasia (BPH). Furthermore, classification systems for
patients with PCa which are used for evaluating potential genetic associations with PCa
progression differ between studies, which together with small sizes of patient groups, calls for
replication of acquired statistically significant data.
All of these issues are a potential reason for the opposing results on the association of the most
of genetic variants analyzed in multiple studies with PCa risk and progression. Therefore, in
order to elucidate the effect of these genetic variants, meta-analyses of eligible studies are
frequently conducted. Combining the results from smaller studies through data synthesis in
meta-analysis could result in increased statistical power [181]. Therefore, meta-analyses could
provide more precise estimations, as well as the insight in the potential effect of confounders
[182], such as ethnicity, participant recruitment strategy, or study size.
6. Future perspectives
The main aim of genetic association studies on PCa is the identification of potential PCa genetic
markers which could be used for constructing reliable algorithms for evaluating the risk for
PCa development and/or PCa progression [1]. Therefore, it is important not only to identify
these PCa-related genetic variants, but also to precisely characterize their effect sizes. In order
to do that, ethnic differences need to be taken into account [179]. Other important issues in
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interpreting results of association studies are gene–gene and gene-environment interactions.
Therefore, future research and designing such algorithms require integration of knowledge
on genetic associations, cellular pathways, and statistical epistasis in which real biological
interaction could be reflected.
Since the major problem in clinical practice related to PCa is the overdiagnosis and monitoring
of patients [4], additional studies on PCa aggressiveness with clinically well characterized
groups of PCa patients are needed to identify genetic variants associated with PCa progression
risk. The later implementation of algorithms based on these genetic variants could greatly
improve clinical protocols in monitoring and treating PCa.
7. Conclusion
The efforts for improving clinical protocols in PCa diagnostics, monitoring and treatment
resulted in conducting genetic association studies on PCa. These studies aim to identify
potential PCa genetic markers and characterize their association with PCa risk and/or pro‐
gression through measuring effect sizes. The identified and validated genetic markers could
then be used for constructing reliable algorithms for evaluating the risk for PCa development
and, more importantly, for PCa progression. Implementing such algorithms in clinical practice
is expected to improve the distinction between early diagnosed PCa cases that require
aggressive treatment and latent PCa cases which remain indolent during patient’s lifetime.
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